Chronic lymphocytic leukaemia

  title={Chronic lymphocytic leukaemia},
  author={M. Hallek and T. Shanafelt and B. Eichhorst},
  journal={The Lancet},
  • M. Hallek, T. Shanafelt, B. Eichhorst
  • Published 2018
  • Medicine
  • The Lancet
  • Important advances in understanding the pathogenesis of chronic lymphocytic leukaemia in the past two decades have led to the development of new prognostic tools and novel targeted therapies that have improved clinical outcome. Chronic lymphocytic leukaemia is the most common type of leukaemia in developed countries, and the median age at diagnosis is 72 years. The criteria for initiating treatment rely on the Rai and Binet staging systems and on the presence of disease-related symptoms. For… CONTINUE READING
    290 Citations

    Topics from this paper

    Recent advances in chronic lymphocytic leukemia therapy
    • PDF
    Pathogenesis of chronic lymphocytic leukemia and the development of novel therapeutic strategies
    • Y. Kikushige
    • Medicine
    • Journal of clinical and experimental hematopathology : JCEH
    • 2020
    • PDF
    Guidelines for Diagnosis and Treatment of Chronic Lymphocytic Leukemia. Krohem B-Cll 2017
    • 3
    • Highly Influenced
    • PDF
    A Study of Genomic Instability in Chronic Lymphocytic Leukaemia (CLL)
    • PDF
    Precision Medicine Management of Chronic Lymphocytic Leukemia
    • 9
    • Highly Influenced
    • PDF
    The expanding role of venetoclax in chronic lymphocytic leukemia and small lymphocytic lymphoma
    • 3
    • PDF
    [Chronic lymphocytic leukemia].
    Measurable residual disease in the treatment of chronic lymphocytic leukemia
    • PDF


    Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
    • 1,058
    • PDF
    State-of-the-Art Treatment and Novel Agents in Chronic Lymphocytic Leukemia
    • 22
    Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia.
    • 993
    • PDF